Citations (30)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Tzu Hsiang Chien, Andrea Puig, Thang Khuong, Mahsa H Kouhkamari, Samuel Che & Tom Hsun-Wei Huang. (2021) An Australian Real-World Study of Treatment Persistence of Ustekinumab in Crohn’s Disease. Biologics: Targets and Therapy 15, pages 237-245.
Read now
Read now
Anders Forss, Mark Clements, Pär Myrelid, Hans Strid, Charlotte Söderman, Agnieszka Wagner, David Andersson, Fredrik Hjelm, Ola Olén, Jonas F. Ludvigsson & Jonas Halfvarson. (2021) Prospective observational study on Stelara (ustekinumab) assessing effectiveness in Crohn’s disease (PROSE): a 16-week follow-up. Scandinavian Journal of Gastroenterology 56:6, pages 680-686.
Read now
Read now
Fabio Salvatore Macaluso, Walter Fries, Anna Viola, Giuseppe Costantino, Marco Muscianisi, Maria Cappello, Laura Guida, Enrica Giuffrida, Antonio Magnano, Dario Pluchino, Concetta Ferracane, Giovanni Magrì, Roberto Di Mitri, Filippo Mocciaro, Antonino Carlo Privitera, Salvatore Camilleri, Serena Garufi, Sara Renna, Angelo Casà, Barbara Scrivo, Marco Ventimiglia & Ambrogio Orlando. (2020) Effectiveness of Ustekinumab on Crohn‘s Disease Associated Spondyloarthropathy: Real-World Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD). Expert Opinion on Biological Therapy 20:11, pages 1381-1384.
Read now
Read now
Articles from other publishers (27)
Sisi Zhou & Jing Yu. (2023) Crohn’s disease and breast cancer: a literature review of the mechanisms and treatment. Internal and Emergency Medicine 18:5, pages 1303-1316.
Crossref
Crossref
María José García, Montserrat Rivero, Agnès Fernández-Clotet, Ruth de Francisco, Beatriz Sicilia, Francisco Mesonero, María Luisa de Castro, María José Casanova, Federico Bertoletti, Francisco Javier García-Alonso, Alicia López-García, Raquel Vicente, Xavier Calvet, Manuel Barreiro-de Acosta, Juan Ferrer Rosique, Pilar Varela Trastoy, Alejandro Nuñez, Elena Ricart, Sabino Riestra, Lara Arias García, María Rodríguez, Laura Arranz, Ramón Pajares, Raquel Mena, Margalida Calafat, Patricia Camo, Fernando Bermejo, Ángel Ponferrada, Rosa Eva Madrigal, Jordina Llaó, Eva Sesé, Eugenia Sánchez, Juan Ramón Pineda Mariño, Carlos González Muñoza, Ana Yaiza Carbajo López, Ana Belén Julián, Albert Villoria Ferrer, Iria Baston-Rey, Lorena Jara, Pedro Almela, Laura Codesido, Saioa de la Maza, Carles Leal, Berta Caballol, Isabel Pérez-Martínez, Raquel Vinuesa Campo, Javier Crespo, Eugeni Domènech, María Chaparro & Javier P Gisbert. (2023) Comparative Study of the Effectiveness of Vedolizumab Versus Ustekinumab After Anti-TNF Failure in Crohn’s Disease (Versus-CD): Data from the ENEIDA Registry. Journal of Crohn's and Colitis.
Crossref
Crossref
Elisa Proietti, Renske W M Pauwels, Christien J van der Woude, Michael Doukas, Lindsey Oudijk, Maikel P Peppelenbosch, Ursula Grohmann, Marie-Rose B S Crombag, Annemarie C de Vries & Gwenny M Fuhler. (2023) Ustekinumab Tissue and Serum Levels in Patients With Crohn’s Disease Are Closely Correlated Though Not Consistently Associated With Objective Response After Induction. Inflammatory Bowel Diseases 29:7, pages 1038-1046.
Crossref
Crossref
Fabio Salvatore Macaluso, Claudio Papi, Ambrogio Orlando, Stefano Festa, Daniela Pugliese, Stefanos Bonovas, Claudia Pansieri, Daniele Piovani, Gionata Fiorino, Massimo Claudio Fantini, Flavio Caprioli, Marco Daperno, Alessandro Armuzzi, Lorenzo Bertani, Cristina Bezzio, Giorgia Bodini, Fabrizio Bossa, Andrea Buda, Emma Calabrese, Federica Furfaro, Salvatore Leone, Filippo Mocciaro, Sara Onali, Luca Pastorelli, Enrica Previtali, Mariabeatrice Principi, Sara Renna, Davide Giuseppe Ribaldone, Antonio Rispo, Fernando Rizzello, Simone Saibeni, Gianluca Matteo Sampietro, Edoardo Savarino, Anna Testa, Angela Variola, Angelo Viscido, Sandro Ardizzone, Livia Biancone, Maria Cappello, Fabiana Castiglione, Rachele Ciccocioppo, Michele Comberlato, Francesco Costa, Renata D'Incà, Silvio Danese, Antonio Di Sabatino, Walter Fries, Paolo Gionchetti, Giovanni Latella, Francesco Manguso, Mauro Mastronardi, Gianmichele Meucci, Monica Milla, Maria Lia Scribano & Maurizio Vecchi. (2023) Use of biologics for the management of Crohn's disease: IG-IBD clinical guidelines based on the GRADE methodology. Digestive and Liver Disease 55:4, pages 442-453.
Crossref
Crossref
Fabio Salvatore Macaluso, Mauro Grova, Marica Saladino, Maria Cappello, Maria Giulia Demarzo, Antonino Carlo Privitera, Emiliano Giangreco, Serena Garufi, Sara Renna, Angelo Casà, Marco Ventimiglia, Walter Fries & Ambrogio Orlando. (2023) The effectiveness of ustekinumab and vedolizumab as third-line biologic therapy in patients with Crohn's disease. Digestive and Liver Disease 55:4, pages 471-477.
Crossref
Crossref
Nathalie Van den Berghe, Bram Verstockt, Séverine Vermeire, Debby Thomas & Paul Declerck. (2023) Higher Drug Exposure During the First 24 Weeks of Ustekinumab Treatment Is Associated With Endoscopic Remission in Crohn’s Disease. Clinical Gastroenterology and Hepatology 21:3, pages 838-840.e2.
Crossref
Crossref
María Chaparro, Iria Baston-Rey, Estela Fernández-Salgado, Javier González García, Laura Ramos, María Teresa Diz-Lois Palomares, Federico Argüelles-Arias, Eva Iglesias Flores, Mercedes Cabello, Saioa Rubio Iturria, Andrea Núñez Ortiz, Mara Charro, Daniel Ginard, Carmen Dueñas Sadornil, Olga Merino Ochoa, David Busquets, Eduardo Iyo, Ana Gutiérrez Casbas, Patricia Ramírez de la Piscina, Marta Maia Boscá-Watts, Maite Arroyo, María José García, Esther Hinojosa, Jordi Gordillo, Pilar Martínez Montiel, Benito Velayos Jiménez, Cristina Quílez Ivorra, Juan María Vázquez Morón, José María Huguet, Yago González-Lama, Ana Isabel Muñagorri Santos, Víctor Manuel Amo, María Dolores Martín-Arranz, Fernando Bermejo, Jesús Martínez Cadilla, Cristina Rubín de Célix, Paola Fradejas Salazar, Antonio López San Román, Nuria Jiménez, Santiago García López, Anna Figuerola, Itxaso Jiménez, Francisco José Martínez Cerezo, Carlos Taxonera, Pilar Varela, Ruth de Francisco, David Monfort, Gema Molina Arriero, Alejandro Hernández Camba, Francisco Javier García-Alonso, Manuel Van Domselaar, Ramón Pajares Villarroya, Alejandro Núñez, Francisco Rodríguez Moranta, Ignacio Marín-Jiménez, Virginia Robles Alonso, María del Mar Martín Rodríguez, Patricia Camo-Monterde, Iván García Tercero, Mercedes Navarro Llavat, Lara Arias García, Daniel Hervías Cruz, Sara Sulleiro, Cynthia Novella, Eugenia Vispo, Manuel Barreiro-de Acosta & Javier P Gisbert. (2022) Long-Term Real-World Effectiveness and Safety of Ustekinumab in Crohn’s Disease Patients: The SUSTAIN Study. Inflammatory Bowel Diseases 28:11, pages 1725-1736.
Crossref
Crossref
Sara OnaliDaniela PuglieseFlavio Andrea CaprioliAmbrogio OrlandoLivia BianconeOlga Maria NardoneNicola ImperatoreGionata FiorinoMaria CappelloAnna ViolaMaria Beatrice PrincipiCristina BezzioAnnalisa AratariSonia CarparelliSilvia MazzuoliFrancesco MangusoLaurino GrossiGiorgia BodiniDavide RibaldoneGiammarco MocciAgnese Miranda, Luigi MinerbaAgnese FavaleMauro GrovaLudovica ScucchiSimone SegatoWalter FriesFabiana CastiglioneAlessandro ArmuzziMassimo C. Fantini. (2022) An Objective Comparison of Vedolizumab and Ustekinumab Effectiveness in Crohn's Disease Patients' Failure to TNF-Alpha Inhibitors. American Journal of Gastroenterology 117:8, pages 1279-1287.
Crossref
Crossref
Cristina Rubín de Célix, María Chaparro & Javier P. Gisbert. (2022) Real-World Evidence of the Effectiveness and Safety of Ustekinumab for the Treatment of Crohn’s Disease: Systematic Review and Meta-Analysis of Observational Studies. Journal of Clinical Medicine 11:14, pages 4202.
Crossref
Crossref
Mohammed Assem Khorshid, Ahmed Cordie & Sherief Abd-Elsalam. (2022) Safety and Efficacy of Ustekinumab in the Treatment of Crohn Disease: A Systematic Review and Meta-analysis. Journal of Coloproctology 42:02, pages 178-186.
Crossref
Crossref
Fabio Salvatore Macaluso, Ambrogio Orlando, Claudio Papi, Stefano Festa, Daniela Pugliese, Stefanos Bonovas, Claudia Pansieri, Daniele Piovani, Gionata Fiorino, Massimo Claudio Fantini, Flavio Caprioli, Marco Daperno, Alessandro Armuzzi, Lorenzo Bertani, Cristina Bezzio, Giorgia Bodini, Fabrizio Bossa, Andrea Buda, Emma Calabrese, Federica Furfaro, Salvatore Leone, Filippo Mocciaro, Sara Onali, Luca Pastorelli, Enrica Previtali, Mariabeatrice Principi, Sara Renna, Davide Giuseppe Ribaldone, Antonio Rispo, Fernando Rizzello, Simone Saibeni, Gianluca Matteo Sampietro, Edoardo Savarino, Anna Testa, Angela Variola, Angelo Viscido, Sandro Ardizzone, Livia Biancone, Maria Cappello, Fabiana Castiglione, Rachele Ciccocioppo, Michele Comberlato, Francesco Costa, Renata D'Incà, Silvio Danese, Antonio Di Sabatino, Walter Fries, Paolo Gionchetti, Giovanni Latella, Francesco Manguso, Mauro Mastronardi, Gianmichele Meucci, Monica Milla, Maria Lia Scribano & Maurizio Vecchi. (2022) Use of biologics and small molecule drugs for the management of moderate to severe ulcerative colitis: IG-IBD clinical guidelines based on the GRADE methodology. Digestive and Liver Disease 54:4, pages 440-451.
Crossref
Crossref
Andreas Sturm, Raja Atreya, Dominik Bettenworth, Bernd Bokemeyer, Axel Dignaß, Robert Ehehalt, Christoph Germer, Philip C. Grunert, Ulf Helwig, Klaus Herrlinger, Peter Kienle, Martin E. Kreis, Torsten Kucharzik, Jost Langhorst, Christian Maaser, Johann Ockenga, Claudia Ott, Britta Siegmund, Sebastian Zeißig & Andreas Stallmach. (2022) Aktualisierte S3-Leitlinie „Diagnostik und Therapie des Morbus Crohn“ der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) – August 2021 – AWMF-Registernummer: 021-004. Zeitschrift für Gastroenterologie 60:03, pages 332-418.
Crossref
Crossref
Sailish Honap, Susanna Meade, Hajir Ibraheim, Peter M. Irving, Michael P. Jones & Mark A. Samaan. (2021) Effectiveness and Safety of Ustekinumab in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. Digestive Diseases and Sciences 67:3, pages 1018-1035.
Crossref
Crossref
Fabio Salvatore Macaluso, Marcello Maida, Marco Ventimiglia & Ambrogio Orlando. (2022) Effectiveness and safety of tofacitinib for the treatment of ulcerative colitis: A single-arm meta-analysis of observational studies. Digestive and Liver Disease 54:2, pages 183-191.
Crossref
Crossref
Aditi Kumar, Alexander Cole, Jonathan Segal, Philip Smith & Jimmy K. Limdi. (2022) A review of the therapeutic management of Crohn’s disease. Therapeutic Advances in Gastroenterology 15, pages 175628482210784.
Crossref
Crossref
Maria Lia Scribano, Annalisa Aratari, Benedetto Neri, Cristina Bezzio, Paola Balestrieri, Valentina Baccolini, Giuliano Falasco, Caterina Camastra, Paolo Pantanella, Rita Monterubbianesi, Alessandro Tullio, Simone Saibeni, Claudio Papi, Livia Biancone, Rocco Cosintino & Roberto Faggiani. (2022) Effectiveness of ustekinumab in patients with refractory Crohn’s disease: a multicentre real-life study in Italy. Therapeutic Advances in Gastroenterology 15, pages 175628482110724.
Crossref
Crossref
Mario Fernández-Ruiz. 2022. Infectious Complications in Biologic and Targeted Therapies. Infectious Complications in Biologic and Targeted Therapies
199
217
.
Javier P. Gisbert & María Chaparro. (2021) Primary Failure to an Anti-TNF Agent in Inflammatory Bowel Disease: Switch (to a Second Anti-TNF Agent) or Swap (for Another Mechanism of Action)?. Journal of Clinical Medicine 10:22, pages 5318.
Crossref
Crossref
Flavio Caprioli, Marco Daperno, Ivana Bravatà, Alessia Brigido, Daniela Frigerio, Ottavio Secchi & Antonio Rispo. (2021) Who are the patients with Crohn’s disease unsuitable to receive an anti-TNFα therapy? Results from a survey of Italian physicians and literature review. European Journal of Gastroenterology & Hepatology 33:8, pages 1082-1090.
Crossref
Crossref
Anthony Buisson, Stéphane Nancey, Luc Manlay, David T Rubin, Xavier Hebuterne, Benjamin Pariente, Mathurin Fumery, David Laharie, Xavier Roblin, Gilles Bommelaer, Bruno Pereira, Laurent Peyrin‐Biroulet & Lucine Vuitton. (2021) Ustekinumab is more effective than azathioprine to prevent endoscopic postoperative recurrence in Crohn's disease. United European Gastroenterology Journal 9:5, pages 552-560.
Crossref
Crossref
Vineet S. Rolston, Jessica Kimmel, Violeta Popov, Brian P. Bosworth, David Hudesman, Lisa B. Malter, Simon Hong & Shannon Chang. (2020) Ustekinumab Does Not Increase Risk of Adverse Events: A Meta-Analysis of Randomized Controlled Trials. Digestive Diseases and Sciences 66:5, pages 1631-1638.
Crossref
Crossref
Anna Viola, Marco Muscianisi, Fabio S Macaluso, Marco Ventimiglia, Maria Cappello, Antonino C Privitera, Antonio Magnano, Dario Pluchino, Giovanni Magrì, Concetta Ferracane, Filippo Mocciaro, Serena Garufi, Enrica Giuffrida, Giuseppe Costantino, Gabriele Fiocco, Mauro Grova, Laura Guida, Angela Alibrandi, Ambrogio Orlando & Walter Fries. (2021) Ustekinumab in Crohn's disease: Real‐world outcomes from the Sicilian network for inflammatory bowel diseases. JGH Open 5:3, pages 364-370.
Crossref
Crossref
Fabio Salvatore Macaluso, Marcello Maida, Mauro Grova, Federica Crispino, Giulia Teresi, Adele Orlando & Ambrogio Orlando. (2021) Head-to-head comparison of biological drugs for inflammatory bowel disease: from randomized controlled trials to real-world experience. Therapeutic Advances in Gastroenterology 14, pages 175628482110106.
Crossref
Crossref
Tristan Townsend, Violeta Razanskaite, Susanna Dodd, Daniel Storey, Stephanie Michail, James Morgan, Michael Davies, Douglas Penman, Christopher Watters, Mira Swaminathan, Joseph Sabine, Adam Chapman, Philip J Smith, Paul K. Flanagan, Ian Reilly, Keith Bodger & Sreedhar Subramanian. (2020) Comparative effectiveness of ustekinumab or vedolizumab after one year in 130 patients with anti‐TNF‐refractory Crohn’s disease. Alimentary Pharmacology & Therapeutics 52:8, pages 1341-1352.
Crossref
Crossref
Thomas Lambin, Adam S. Faye & Jean-Frédéric Colombel. (2020) Inflammatory Bowel Disease Therapy and Venous Thromboembolism. Current Treatment Options in Gastroenterology 18:3, pages 462-475.
Crossref
Crossref
Laura Lorenzo González, Teresa Valdés Delgado, Juan María Vázquez Morón, Luisa Castro Laria, Eduardo Leo Carnerero, María Belén Maldonado Pérez, Damián Sánchez Capilla, Héctor Pallarés Manrique, Antonia Sáez Díaz & Federico Argüelles Arias. (2020) Ustekinumab in Crohn's disease: real-world outcomes and predictors of response.. Revista Española de Enfermedades Digestivas.
Crossref
Crossref
Renske W. M. Pauwels, Christien J. van der Woude, Nicole S. Erler & Annemarie C. de Vries. (2020) Fecal calprotectin is an early predictor of endoscopic response and histologic remission after the start of vedolizumab in inflammatory bowel disease. Therapeutic Advances in Gastroenterology 13, pages 175628482097976.
Crossref
Crossref